Although an objective response rate of 69% was observed in the EZH2- mutant cohort of a phase 2 trial in patients with follicular lymphoma, EZH2 inhibitors have so far shown limited effectiveness in most solid tumors, particularly in the pediatric population1,4,12. Here, EZH2 is linked to follicular lymphoma.